We are international
Donate
TEXT SIZE   


Understanding VELCADE® (bortezomib) for Injection Therapy
07.05.11
You can view the entire document as a PDF by clicking on the PDF tab above or by requesting a free hard copy from the Foundation.

This booklet has been developed to help you learn more about VELCADE® (bortezomib). After reading this booklet, you should know:

  • What VELCADE® is
  • How VELCADE® works
  • The possible side effects of VELCADE®
  • How VELCADE® is given.

This booklet is meant to provide you with general information only. It is not meant to replace the advice of your doctor or nurse. Your doctor or nurse can answer questions related to your specific treatment plan.
 related articles
Understanding VELCADE as a Subcutaneous (SQ) Injection
New! Tip Card on Subcutaneous VELCADE
FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Patients Personifying Progress: Mary Ming-Mosely
Subcutaneous VELCADE® Site
The VELCADE® Website
VELCADE® Downloadable Resources
Open Velcade® (bortezomib) Trials
Eastern Cooperative Oncology Group Clinical Trial:E1A05
Understanding VELCADE® (bortezomib) for Injection
Subcutaneous VELCADE® Approved in the EU for the Treatment of Multiple Myeloma
VELCADE® Webcasts from the 2012 American Society of Clinical Oncology (ASCO) Meeting
VELCADE® Webcasts from the 2011 American Society of Hematology (ASH) Annual Meeting
Millennium's VELCADE Reimbursement Assistance Program
Millennium: The Takeda Oncology Company's Web Site
Archived VELCADE Webcasts
News About VELCADE®


You might also be interested in:

General Information
Understanding VELCADE as a Subcutaneous (SQ) Injection
Two short videos explaining what you need to know about VELCADE SQ.
New! Tip Card on Subcutaneous VELCADE
FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Study met primary efficacy endpoint of non-inferiority between subcutaneous and intravenous administration.
Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy.
Patients Personifying Progress: Mary Ming-Mosely
Two months ago, I started on VELCADE subcutaneous. It’s just a shot. I don’t have to wait for an IV. It’s just in-and-out. VELCADE has kept me going and feeling well enough to live my life.
Subcutaneous VELCADE® Site
The US Food and Drug Administration (FDA) has approved subcutaneous VELCADE for the treatment of multiple myeloma. This approval was based on a large, international clinical trial that studied VELCADE injected under the skin compared with VELCADE injected into a vein. The 222 patients in this study had been treated for their myeloma and relapsed.
The VELCADE® Website
Information for patients and clinicans on indications and usage.
VELCADE® Downloadable Resources
Clinical Trials
Open Velcade® (bortezomib) Trials
Eastern Cooperative Oncology Group Clinical Trial:E1A05
Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®) & Lenalidomide (Revlimid®) - Dexamethasone (VRD) versus Bortezomib (Velcade®:) - Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen
Publications
Understanding VELCADE® (bortezomib) for Injection
Part of the IMF's Understanding series, this booklet covers the basics, including: What is VELCADE®? How does it work? How is VELCADE® given? How is it used in clinical practice today? What are the side effects?
News
Subcutaneous VELCADE® Approved in the EU for the Treatment of Multiple Myeloma
The approval is based on data from a Phase III study demonstrating that subcutaneous administration of bortezomib is equally effective as intravenous bortezomib but is associated with a significant reduction in the frequency and severity of side effects.
Webcasts About Velcade
VELCADE® Webcasts from the 2012 American Society of Clinical Oncology (ASCO) Meeting
VELCADE® Webcasts from the 2011 American Society of Hematology (ASH) Annual Meeting
The experts talk about VELCADE® in clinical trials, as frontline therapy and for relapsed patients, alone and in trials with various other agents in nine webcasts.
Links
Millennium's VELCADE Reimbursement Assistance Program
Program is available to patients, physicians, and caregivers to provide assistance regarding reimbursement issues related to the use of VELCADE® (bortezomib) for Injection.
Millennium: The Takeda Oncology Company's Web Site
Archive
Archived VELCADE Webcasts
Webcasts on VELCADE research from past medical meetings.
News About VELCADE®
Past articles and press releases about VELCADE.
12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421 | USA
Hotline:800-452-2873 or 818-487-7455
©2012 International Myeloma Foundation. All Rights Reserved. 		•about myeloma    | •treatment options | •health professionals   | • support   | • webcasts   | • meetings   | • advocacy   | • fundraising   | • media   | • blogs   | • about imf   | Privacy Statement | Annual Report | Audit Report | Federal Tax Form 990 | Facebook | Twitter | mission statement |